These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 22278426)

  • 1. Serum osteoprotegerin, RANKL, and Dkk-1 levels in adults with Langerhans cell histiocytosis.
    Makras P; Polyzos SA; Anastasilakis AD; Terpos E; Kanakis G; Schini M; Papatheodorou A; Kaltsas GA
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E618-21. PubMed ID: 22278426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin, and RANKL in patients with Paget's disease of bone.
    Polyzos SA; Anastasilakis AD; Efstathiadou Z; Kita M; Litsas I; Avramidis A; Arsos G; Moralidis E; Gerou S; Pavlidou V; Papatheodorou A; Terpos E
    Horm Metab Res; 2009 Nov; 41(11):846-50. PubMed ID: 19670154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis.
    Ishii R; Morimoto A; Ikushima S; Sugimoto T; Asami K; Bessho F; Kudo K; Tsunematu Y; Fujimoto J; Imashuku S
    Pediatr Blood Cancer; 2006 Aug; 47(2):194-9. PubMed ID: 16358318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum receptor activator of nuclear factor κB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy.
    Todenhöfer T; Hennenlotter J; Leidenberger P; Wald A; Hohneder A; Kühs U; Mischinger J; Aufderklamm S; Gakis G; Blumenstock G; Stenzl A; Schwentner C
    BJU Int; 2014 Jan; 113(1):152-9. PubMed ID: 23360112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale for the application of RANKL inhibition in the treatment of Langerhans cell histiocytosis.
    Makras P; Salagianni M; Revelos K; Anastasilakis AD; Schini M; Tsoli M; Kaltsas G; Andreakos E
    J Clin Endocrinol Metab; 2015 Feb; 100(2):E282-6. PubMed ID: 25375981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis.
    Świerkot J; Gruszecka K; Matuszewska A; Wiland P
    Arch Immunol Ther Exp (Warsz); 2015 Oct; 63(5):397-404. PubMed ID: 25837853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoprotegerin/RANKL system imbalance in active polyarticular-onset juvenile idiopathic arthritis: a bone damage biomarker?
    Spelling P; Bonfá E; Caparbo VF; Pereira RM
    Scand J Rheumatol; 2008; 37(6):439-44. PubMed ID: 18802807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of sclerostin/dickkopf-1 and receptor activator of nuclear factor kB ligand/osteoprotegerin signalling pathways in the development of osteoporosis in patients with haemophilia A and B: A cross-sectional study.
    Anagnostis P; Vakalopoulou S; Christoulas D; Paschou SA; Papatheodorou A; Garipidou V; Kokkoris P; Terpos E
    Haemophilia; 2018 Mar; 24(2):316-322. PubMed ID: 29194852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RANKL/OPG ratio and DKK-1 expression in primary osteoblastic cultures from osteoarthritic and osteoporotic subjects.
    Corrado A; Neve A; Macchiarola A; Gaudio A; Marucci A; Cantatore FP
    J Rheumatol; 2013 May; 40(5):684-94. PubMed ID: 23457386
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum levels of the decoy receptor osteoprotegerin in children with Langerhans cell histiocytosis.
    Rosso DA; Karis J; Braier JL; Henter JI; Fadeel B
    Pediatr Res; 2006 Feb; 59(2):281-6. PubMed ID: 16439593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of alendronate treatment on serum levels of osteoprotegerin and total receptor activator of nuclear factor kappaB in women with postmenopausal osteoporosis.
    Reyes-García R; Muñoz-Torres M; García DF; Mezquita-Raya P; García Salcedo JA; de Dios Luna J
    Menopause; 2010; 17(1):140-4. PubMed ID: 19574937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Correlation of RANKL/OPG, dickkopf-1 and bone marrow edema in rheumatoid arthritis with the complaint of knee pain].
    Li M; Wu XH; Yin G; Xie QB
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2015 Mar; 46(2):276-9. PubMed ID: 25924445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Wnt/β-catenin and RANKL/OPG in bone healing of diabetic Charcot arthropathy patients.
    Folestad A; Ålund M; Asteberg S; Fowelin J; Aurell Y; Göthlin J; Cassuto J
    Acta Orthop; 2015; 86(4):415-25. PubMed ID: 25811776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Bisbinas I; Gerou S; Makras P
    J Clin Endocrinol Metab; 2013 Aug; 98(8):3206-12. PubMed ID: 23788684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imbalance of the osteoprotegerin/RANKL ratio in bone marrow microenvironment after allogeneic hemopoietic stem cell transplantation.
    Ricci P; Tauchmanova L; Risitano AM; Carella C; Mazziotti G; Lombardi G; Colao A; Rotoli B; Selleri C
    Transplantation; 2006 Dec; 82(11):1449-56. PubMed ID: 17164716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationships among serum receptor of nuclear factor-kappaB ligand, osteoprotegerin, high-sensitivity C-reactive protein, and bone mineral density in postmenopausal women: osteoimmunity versus osteoinflammatory.
    Nabipour I; Larijani B; Vahdat K; Assadi M; Jafari SM; Ahmadi E; Movahed A; Moradhaseli F; Sanjdideh Z; Obeidi N; Amiri Z
    Menopause; 2009; 16(5):950-5. PubMed ID: 19387415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.
    Poornima IG; Mackey RH; Buhari AM; Cauley JA; Matthews KA; Kuller LH
    Menopause; 2014 Jul; 21(7):702-10. PubMed ID: 24473535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Below-knee arterial calcification in type 2 diabetes: association with receptor activator of nuclear factor κB ligand, osteoprotegerin, and neuropathy.
    Bourron O; Aubert CE; Liabeuf S; Cluzel P; Lajat-Kiss F; Dadon M; Komajda M; Mentaverri R; Brazier M; Pierucci A; Morel F; Jacqueminet S; Massy ZA; Hartemann A
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4250-8. PubMed ID: 25013993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand system in the early post-operative period of liver transplantation.
    Fábrega E; Orive A; García-Unzueta M; Amado JA; Casafont F; Pons-Romero F
    Clin Transplant; 2006; 20(3):383-8. PubMed ID: 16824158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in serum levels of receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, IL-6 and TNF-alpha in patients with a concomitant head injury and fracture.
    Lee JS; Ryu CH; Moon NH; Kim SJ; Park SY; Suh KT
    Arch Orthop Trauma Surg; 2009 May; 129(5):711-8. PubMed ID: 18427820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.